PFS and OS among patients who achieved CR/CRu consolidation
| . | PFS, y or % (95% CI) . | OS, y or % (95% CI) . |
|---|---|---|
| Overall | ||
| Median | 4.6 y (3.4-5.8) | 9.2 y (7.4-12.0) |
| 1 y | 80% (76-84) | 93% (90-96) |
| 2 y | 67% (62-72) | 85% (81-89) |
| 5 y | 46% (41-53) | 65% (59-71) |
| 10 y | 29% (23-36) | 46% (39-54) |
| Induction regimen | ||
| R-MPV | ||
| Median | 7.0 y (4.6-13.0) | 12.0 y (9.7-NR) |
| 1 y | 84% (79-90) | 93% (89-97) |
| 2 y | 71% (65-78) | 86% (81-91) |
| 5 y | 56% (49-65) | 76% (69-83) |
| 10 y | 40% (31-52) | 60% (49-74) |
| MPV | ||
| Median | 3.0 y (2.1-5.8) | 6.2 y (5.0-9.3) |
| 1 y | 75% (66-85) | 94% (88-99) |
| 2 y | 61% (51-72) | 83% (75-92) |
| 5 y | 38% (29-51) | 59% (49-72) |
| 10 y | 20% (13-32) | 36% (26-49) |
| Other (all) | ||
| Median | 3.0 y (2.2-4.8) | 4.8 y (4.2-9.2) |
| 1 y | 73% (64-84) | 92% (85-98) |
| 2 y | 63% (53-75) | 82% (74-92) |
| 5 y | 31% (21-47) | 49% (37-65) |
| 10 y | 17% (8.7-32) | 32% (21-49) |
| Other (MTX containing, n = 66) | ||
| Median | 3.0 y (2.2-5.2) | 5.0 y (4.2-9.2) |
| 1 y | 76% (66-87) | 92% (86-99) |
| 2 y | 64% (53-77) | 86% (77-95) |
| 5 y | 35% (24-52) | 51% (38-67) |
| 10 y | 19% (10-36) | 31% (19-50) |
| Other (non-MTX containing, n = 6) | ||
| Median | 1.6 y (0.78-NR) | 3.3 y (1.2-NR) |
| 1 y | 50% (22-100) | 83% (58-100) |
| 2 y | 50% (22-100) | 50% (22-100) |
| 5 y | − | 33% (11-100) |
| 10 y | − | 33% (11-100) |
| . | PFS, y or % (95% CI) . | OS, y or % (95% CI) . |
|---|---|---|
| Overall | ||
| Median | 4.6 y (3.4-5.8) | 9.2 y (7.4-12.0) |
| 1 y | 80% (76-84) | 93% (90-96) |
| 2 y | 67% (62-72) | 85% (81-89) |
| 5 y | 46% (41-53) | 65% (59-71) |
| 10 y | 29% (23-36) | 46% (39-54) |
| Induction regimen | ||
| R-MPV | ||
| Median | 7.0 y (4.6-13.0) | 12.0 y (9.7-NR) |
| 1 y | 84% (79-90) | 93% (89-97) |
| 2 y | 71% (65-78) | 86% (81-91) |
| 5 y | 56% (49-65) | 76% (69-83) |
| 10 y | 40% (31-52) | 60% (49-74) |
| MPV | ||
| Median | 3.0 y (2.1-5.8) | 6.2 y (5.0-9.3) |
| 1 y | 75% (66-85) | 94% (88-99) |
| 2 y | 61% (51-72) | 83% (75-92) |
| 5 y | 38% (29-51) | 59% (49-72) |
| 10 y | 20% (13-32) | 36% (26-49) |
| Other (all) | ||
| Median | 3.0 y (2.2-4.8) | 4.8 y (4.2-9.2) |
| 1 y | 73% (64-84) | 92% (85-98) |
| 2 y | 63% (53-75) | 82% (74-92) |
| 5 y | 31% (21-47) | 49% (37-65) |
| 10 y | 17% (8.7-32) | 32% (21-49) |
| Other (MTX containing, n = 66) | ||
| Median | 3.0 y (2.2-5.2) | 5.0 y (4.2-9.2) |
| 1 y | 76% (66-87) | 92% (86-99) |
| 2 y | 64% (53-77) | 86% (77-95) |
| 5 y | 35% (24-52) | 51% (38-67) |
| 10 y | 19% (10-36) | 31% (19-50) |
| Other (non-MTX containing, n = 6) | ||
| Median | 1.6 y (0.78-NR) | 3.3 y (1.2-NR) |
| 1 y | 50% (22-100) | 83% (58-100) |
| 2 y | 50% (22-100) | 50% (22-100) |
| 5 y | − | 33% (11-100) |
| 10 y | − | 33% (11-100) |
PFS, progression-free survival; OS, overall survival; MPV, methotrexate, procarbazine, vincristine; R, rituximab; MTX, methotrexate; CI, confidence interval; y, year.